ArriVent Biopharma Inc. reported a net loss of $130.8 million for the nine months ended September 30, 2025, compared to a net loss of $59.9 million for the same period in 2024. Research and development expenses were $121.2 million, up from $58.8 million in 2024, including a $40 million one-time upfront payment for the in-licensing of ARR-217. General and administrative expenses reached $17.5 million, compared to $11.8 million in 2024. Net cash used in operations was $129.9 million for the period, up from $54.1 million the previous year. As of September 30, 2025, cash and investments totaled $305.4 million, expected to fund operations into mid-2027. Key business developments included FDA IND clearance for ARR-217, ongoing Phase 1 study in China, and the appointment of Brent S. Rice as Chief Commercial Officer.